The Effect of LM25 and LM50 on Hypoglycemia in Chinese T2DM Patients: Post Hoc Analysis of a Randomized Crossover Trial
Open Access
- 24 January 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 11 (3), 643-654
- https://doi.org/10.1007/s13300-020-00766-5
Abstract
Introduction To investigate the safety of insulin lispro Mix 25 and 50 (LM25 and LM50) in hypoglycemia in patients with type 2 diabetes mellitus (T2DM). Methods This was a post hoc analysis of a phase IV, randomized, crossover clinical trial in Chinese patients with T2DM switching from premixed human insulin 70/30 (PHI70/30) to LM25 or LM50. Eighty-one subjects received a two-stage crossover protocol of either LM25 or LM50 twice daily for 16 weeks. Habitual diet was taken, and self-monitoring of blood glucose (SMBG) was performed throughout the study period. High-carbohydrate diet (HCD), high-fat diet (HFD) and habitual diet patterns were taken, and 72 h continuous glucose monitoring (CGM) was performed at the last 3 days of each treatment stage. Results The frequencies of nocturnal hypoglycemia in LM50 were lower than those in LM25 under a Chinese habitual diet pattern. The related factors of hypoglycemia in patients with T2DM treated with a LM25 or LM50 regimen were the weight-based daily mean insulin dose and the type of combined oral hypoglycemic agents. Under both HCD and habitual diet patterns, the optimal cut point values of bedtime glucose predicting nocturnal hypoglycemia in LM50 were lower than those in LM25. Conclusions The risk of nocturnal hypoglycemia in the LM50 regimen was lower than that in the LM25 regimen under the HCD pattern, and the safety range of bedtime glucose for the LM50 regimen was wider than that of the LM25 regimen in Chinese T2DM patients. Premixed insulin analogs combined with acarbose were more helpful to reduce the incidence of hypoglycemia. Trial Registration http://www.chictr.org.cn #ChiCTR-TTRCC-12002516.Funding Information
- The Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (No. 2017PT32020, No. 2018PT32001)
- Lilly Suzhou Pharmaceutical Co., Ltd. (No)
This publication has 22 references indexed in Scilit:
- Enhancing insulin-use safety in hospitals: Practical recommendations from an ASHP Foundation expert consensus panelAmerican Journal of Health-System Pharmacy, 2013
- Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectablesBMC Public Health, 2013
- Hypoglycemia, With or Without Insulin Therapy, Is Associated With Increased Mortality Among Hospitalized PatientsDiabetes Care, 2013
- Increasing Prevalence of Type 2 Diabetes in Chinese Adults in ShanghaiDiabetes Care, 2012
- Hypoglycemia-associated Mortality Is Not Drug-associated but Linked to ComorbiditiesMaterials, 2011
- Medication incidents reported to an online incident reporting systemEuropean Journal of Clinical Pharmacology, 2011
- Hypoglycemia and Clinical Outcomes in Patients With Diabetes Hospitalized in the General WardDiabetes Care, 2009
- Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulationDiabetes/Metabolism Research and Reviews, 2008
- Factors responsible for deteriorating glucose tolerance in newly diagnosed type 2 diabetes in Japanese menMetabolism, 2006
- Prevalence and consequences of nocturnal hypoglycemia among conventionally treated children with diabetes mellitusThe Journal of Pediatrics, 1990